Remedē Shows Sustained Safety & Efficacy Through 5 Years
Highlights from the 5-year data show sustained improvements that were consistent with the published 6-, 12-, 24-, and 36-month results.
Category: Neurostimulators
Neurostimulators
Latest
Neurostimulators
LatestInspire Upper Airway Stimulation Therapy FDA Approved for 18- to 21-Year-Olds
The US Food and Drug Administration (FDA) has approved an expanded age range for Inspire Upper Airway Stimulation Therapy for obstructive sleep apnea to include 18-21 year old patients.
Neurostimulators
Popular
Which Patients Are Good Candidates for Inspire Upper Airway Stimulation?
As the first FDA-cleared fully implanted neurostimulation device for obstructive sleep apnea becomes available in additional cities throughout the United States, Sleep Review provides guidance on how to screen patients for this therapy.
Inspire Medical Systems Launches New Brand Identity and Website
Inspire Medical Systems Inc, a medical technology company focused on the development and...
Read More
Treatment Benefits of Remedē System Sustained Through 36 Months in Patients with Central Sleep Apnea
Newly published results from 24- and 36-month data from the remed? System Pivotal Trial...
Read More
Toward a Better Understanding of Sleep Surgery
The international sleep medicine community gathered in New York City to discuss hypoglossal...
Read MoreUnited HealthCare to Cover Inspire Sleep Apnea Implant Effective Aug 1
Inspire Medical Systems Inc, a medical technology company that makes an implantable therapy for obstructive sleep apnea (OSA) and is focused on the development and commercialization of minimally invasive solutions for patients...
Read More
2 Sleep Entrepreneurs Recognized in Regional Heartland Awards
Assurance, tax, transaction and advisory services company EY announced the winners of its...
Read More
Company Closes Series 2 Funding Round for Continued Development of Daytime Neurostimulator for Snoring, Mild Sleep Apnea
Signifier Medical Technologies, which is developing the “Snoozeal” daytime...
Read More
Therapy Update: Implanted Neurostimulators for Sleep Apnea
Inspire Medical, Respicardia, LivaNova, and Nyxoah share the latest data on their devices. By Sree...
Read More
More Positive Payor Determinations for Inspire Therapy, Including Additional 10.4 Million Covered Lives
Inspire Medical Systems Inc, a medical technology company that makes an implantable therapy for...
Read More
Upper Airway Stimulation’s Impact on Sleep Apnea Comorbidities
The Inspire implant has been shown to improve sleepiness and functional outcomes. Now researchers...
Read MoreNyxoah Gets European CE Mark Approval for Sleep Apnea Hypoglossal Nerve Stimulation System
Nyxoah SA has received CE Mark approval for the Genio system in Europe. The Genio system is a battery-free, leadless and minimally invasive neurostimulator, capable of delivering bilateral hypoglossal nerve stimulation for...
Read MoreFDA Approves Inspire’s Smaller Profile Sensing Lead for Implanted Neurostimulator
The US Food and Drug Administration (FDA) has approved for use in the United States Inspire Medical Systems Inc’s new sensing lead. Inspire intends to introduce the new sensing lead to its US medical center customers in...
Read MoreInteger Supports Respicardia’s Commercialization in Central Sleep Apnea Market Through New Agreements
Integer, a leading medical device outsource manufacturer, has entered into a new development agreement and a new supply agreement with Respicardia Inc. Under the agreements, Integer will be Respicardia’s development partner and...
Read MoreBlue Cross of Idaho Issues Positive Coverage Policy of Inspire Therapy
Blue Cross of Idaho has issued a positive coverage policy of Inspire Medical Systems Inc’s Inspire upper airway stimulation therapy for obstructive sleep apnea. This is the first coverage policy issued following BCBS...
Read MoreBlue Cross Blue Shield Association’s Evidence Street Issues Positive Assessment for Inspire Therapy
Inspire Medical Systems Inc, a medical technology company that makes an implantable therapy for obstructive sleep apnea (OSA) and is focused on the development and commercialization of minimally invasive solutions for patients...
Read MoreNyxoah Raises €15 Million in New Financing, Completes BLAST OSA Clinical Study
Nyxoah SA, a medical device company focused on the development and commercialization of a hypoglossal nerve stimulation (HGNS) therapy for the treatment of obstructive sleep apnea (OSA), has raised an additional €15 million...
Read More